Pharmaceutical Robots Market Size will grow exponentially from 2022 to 2028 with an increasing need for automation in manufacturing units and high costs of new drug discovery. With the demand for new drugs and medicine soaring, pharmaceutical companies are expected to boost the productivity of automated equipment and robotics.
Automation and robotics have gained traction in the pharmaceutical sector with increasing demand for accuracy, production and increased speed. Asia Pacific, North America and Europe are poised to witness an increasing need for inspection of pharmaceutical drugs. Traditional robots, such as articulated robots, cartesian robots and SCARA robots, along with collaborative robots, will showcase profound growth through 2028.
In terms of product, collaborative market will observe notable growth owing to easy maintenance, affordability and efficiency. Cobots have become sought-after in large facilities as they can be relocated easily, can be programmed for a range of tasks and can start work quickly. Pharmaceutical companies are likely to bank on collaborative robots to boost packaging, marking, dosing and reduce waste. Not to mention, pharma labs will invest in cobots for pick and place operations to optimize complex tasks.
Based on application, picking and packaging application will expand for efficiency and high precision. Prominently, it allows conservation of floor space amidst the demand for limited work envelopes. With the rising demand for tracking, tracing and error-free operation, robots are projected to drive industry growth in the pharmaceutical sector. It is worth mentioning that the demand for personalized packaging will remain instrumental in fostering the business outlook.
Europe pharmaceutical robots market outlook will be strong during the forecast period, mainly due to the demand across laboratory applications. As several tests linked with R&D activities involve repetitive tasks, robots will gain momentum to boost consistency and accuracy. The U.K., Italy, Germany, and France are predicted to bank on pharmaceutical companies amidst increasing demand for efficient workflow management in research laboratories.
Global market share will be propelled by the presence of leading companies, such as Mitsubishi Electric Corporation, Yaskawa Electric Corporation, Stäubli International, Seiko Epson Corporation, Shibuya Corporation, Universal Robots, FANUC Corporation, KUKA, Marchesini Group and ABB, among others. The competitive scenario suggests leading companies would focus on mergers & acquisitions, R&D activities, innovations and partnerships.
In February 2021, ABB revealed two additions to its robot portfolio following the demand for automated production. The company is reported to have registered around a 90% rise in robots sales in China at the end of 2020 and will use cobots to keep up with the demand in the pharmaceutical sector.
Robots have become an attractive option for pharmaceutical companies gearing to tap opportunities across North America and Europe. According to the Robotic Industries Association (IRA), there was around 69% rise in orders for robots from the North American life science companies in 2020 as compared to the preceding year. The COVID-19 outbreak has given the industry the push to boost the adoption of robots to streamline operations. Robots will continue to be used across North America and Europe to reduce the costs and complexity of the process. Recently, it has gained traction to address drug shortages triggered by manufacturing delays.
Pharmaceutical companies are likely to team up with robotics solution providers to integrate technologies into manufacturing, drug development and anti-counterfeiting processes. Robots will potentially flourish as companies enhance investments in the pharmaceutical sector.
Market, by product
Market, by application
The above information is provided for the following regions and countries: